To the full analysis
Buyback calculator for Rhythm Pharmaceuticals
Rhythm Pharmaceuticals stock: key metrics
RYTMRhythm Pharmaceuticals had an operating margin of −101.2% and a return on invested capital (ROIC) of −45.4% in fiscal 2025.
Margins show how much of revenue is left over, returns on capital how hard the invested money works.
Daily figure as of 13 Nov 2026
Margins
- Gross margin
- Operating margin
- Net margin
Figures as a table
| Year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| 2012 | no data | no data | no data |
| 2013 | no data | no data | no data |
| 2014 | no data | no data | no data |
| 2015 | no data | no data | no data |
| 2016 | no data | no data | no data |
| 2017 | no data | no data | no data |
| 2018 | no data | no data | no data |
| 2019 | no data | no data | no data |
| 2020 | no data | no data | no data |
| 2021 | 81.0% | −5,391.9% | −2,207.1% |
| 2022 | 91.0% | −757.9% | −766.2% |
| 2023 | 88.0% | −238.1% | −238.5% |
| 2024 | 89.7% | −204.0% | −200.3% |
| 2025 | 89.7% | −101.2% | −103.6% |
Returns on capital
- ROE
- ROIC
- ROA
Figures as a table
| Year | ROE | ROIC | ROA |
|---|---|---|---|
| 2012 | 50.0% | −87.3% | −95.8% |
| 2013 | 37.3% | no data | −100.0% |
| 2014 | 200.0% | −69.5% | −100.0% |
| 2015 | −34.6% | −52.8% | −29.7% |
| 2016 | −100.0% | no data | −100.0% |
| 2017 | −23.3% | −33.6% | −22.2% |
| 2018 | −30.1% | −31.6% | −28.5% |
| 2019 | −47.9% | −43.5% | −43.6% |
| 2020 | −78.5% | −47.6% | −69.9% |
| 2021 | −24.5% | −59.0% | −21.1% |
| 2022 | −68.5% | −45.0% | −47.4% |
| 2023 | −100.0% | −47.0% | −55.5% |
| 2024 | −100.0% | −74.9% | −66.4% |
| 2025 | −72.8% | −45.4% | −40.9% |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 31 Oct 2018)
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.